Loading...
XCSEBIOPOR
Market cap88mUSD
Dec 20, Last price  
1.48DKK
1D
-6.92%
1Q
-23.32%
Jan 2017
-29.52%
Name

Bioporto A/S

Chart & Performance

D1W1MN
XCSE:BIOPOR chart
P/E
—
P/S
20.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.69%
Rev. gr., 5y
3.54%
Revenues
31m
+6.87%
4,362,0005,554,0008,340,0008,340,00011,008,00013,802,00018,584,00017,858,00016,625,00018,706,00020,383,00020,720,00025,155,00026,016,00026,622,00023,204,00024,254,00028,969,00030,958,000
Net income
-56m
L-25.81%
-15,712,000-16,985,000-15,246,000-14,264,000-16,078,000-14,300,000-14,906,000-14,700,000-20,623,000-12,926,000-10,732,000-22,800,000-32,243,000-38,048,000-69,642,000-61,562,000-57,113,000-75,923,000-56,328,000
CFO
-55m
L+5.66%
-13,881-13,456-14,129,000-13,717,000-13,286,000-13,379,000-13,606,000-15,280,000-16,640,000-16,138,000-16,574,000-19,660,000-29,399,000-38,009,000-60,164,000-35,616,000-64,577,000-52,485,000-55,456,000
Earnings
Feb 20, 2025

Profile

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
URL
https://bioporto.com/
IPO date
Jan 02, 1985
Employees
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
30,958
6.87%
28,969
19.44%
24,254
4.53%
Cost of revenue
91,122
107,913
89,509
Unusual Expense (Income)
NOPBT
(60,164)
(78,944)
(65,255)
NOPBT Margin
Operating Taxes
(4,879)
(5,624)
(6,727)
Tax Rate
NOPAT
(55,285)
(73,320)
(58,528)
Net income
(56,328)
-25.81%
(75,923)
32.93%
(57,113)
-7.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
46,157
92,737
4,361
BB yield
-6.16%
-12.07%
-0.63%
Debt
Debt current
2,970
3,197
2,834
Long-term debt
11,530
18,093
23,234
Deferred revenue
Other long-term liabilities
301
Net debt
(54,630)
(60,502)
(19,455)
Cash flow
Cash from operating activities
(55,456)
(52,485)
(64,577)
CAPEX
(39)
(471)
(389)
Cash from investing activities
(277)
(503)
(412)
Cash from financing activities
40,790
88,699
1,101
FCF
(52,945)
(63,563)
(60,089)
Balance
Cash
66,402
81,792
45,523
Long term investments
2,728
Excess cash
67,582
80,344
44,310
Stockholders' equity
60,160
70,455
46,083
Invested Capital
7,250
10,331
14,905
ROIC
ROCE
EV
Common stock shares outstanding
358,498
331,202
278,052
Price
2.09
-9.91%
2.32
-6.07%
2.47
-38.86%
Market cap
749,261
-2.49%
768,388
11.88%
686,788
-20.39%
EV
694,631
708,120
667,452
EBITDA
(57,486)
(74,978)
(60,926)
EV/EBITDA
Interest
642
1,088
912
Interest/NOPBT